Lung cancer has also served as a proving ground for innovations in cancer therapy: targeted therapies against EGFR, ALK, and KRAS have transformed clinical outcomes; immunotherapies have redefined treatment paradigms; and antibody drug conjugates, bispecific antibodies, T-cell engagers, and cellular therapies are expanding the therapeutic arsenal. This evidence concerns the gene KRAS and cancer.